Chugai Pharmaceutical's latest marketcap:
As of 07/05/2025, Chugai Pharmaceutical's market capitalization has reached $80.95 B. According to our data, Chugai Pharmaceutical is the 255th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 80.95 B |
| Revenue (ttm) | 8.16 B |
| Net Income (ttm) | 2.74 B |
| Shares Out | 0 |
| EPS (ttm) | 1.66 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 06/27/2025 |
| Earnings Date | 07/24/2025 |
Chugai Pharmaceutical's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $80.95 B | 9.84% | 255 |
| 12/30/2024 | $73.28 B | 17.53% | 45345 |
| 12/29/2023 | $62.35 B | 48.41% | 43715 |
| 12/30/2022 | $42.01 B | -21.23% | 42050 |
| 12/30/2021 | $53.34 B | -39.09% | 40180 |
| 12/30/2020 | $87.57 B | 72.72% | 37148 |
| 12/30/2019 | $50.7 B | 60.28% | 34608 |
| 12/28/2018 | $31.63 B | 12.95% | 33338 |
| 12/29/2017 | $28 B | 78.4% | 31927 |
| 12/30/2016 | $15.7 B | -18.24% | 30001 |
Company Profile
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, is a leading pharmaceutical company engaged in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Key Products
- Oncology Products: Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo.
- Other Therapeutic Areas: Actemra (anti-IL-6 receptor), CellCept (immunosuppressant), Edirol (osteoporosis), Enspryng (anti-IL-6 receptor), Evrysdi (spinal muscular atrophy), Hemlibra (anti-coagulation), Mircera (erythropoiesis-stimulating), PiaSky (anti-complement), Ronapreve (anti-SARS-CoV-2), Tamiflu (anti-influenza), and Vabysmo (anti-VEGF/Ang-2).
Strategic Partnerships
The company maintains strategic alliances with the Roche Group and collaborates with Araris Biotech AG to develop antibody-drug conjugates (ADCs) using Araris' AraLinQ technology.
Company Background
Founded in 1925 and headquartered in Chuo-ku, Japan, Chugai Pharmaceutical operates as a subsidiary of Roche Holding Ltd.
Frequently Asked Questions
-
What is Chugai Pharmaceutical's (OTC-CHGCY) current market cap?As of 07/05/2025, Chugai Pharmaceutical (including the parent company, if applicable) has an estimated market capitalization of $80.95 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Chugai Pharmaceutical (OTC-CHGCY) rank globally by market cap?Chugai Pharmaceutical global market capitalization ranking is approximately 255 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.